WO2004056310A3 - Methods of diagnosis and treatment of interstitial lung disease - Google Patents

Methods of diagnosis and treatment of interstitial lung disease Download PDF

Info

Publication number
WO2004056310A3
WO2004056310A3 PCT/US2003/038915 US0338915W WO2004056310A3 WO 2004056310 A3 WO2004056310 A3 WO 2004056310A3 US 0338915 W US0338915 W US 0338915W WO 2004056310 A3 WO2004056310 A3 WO 2004056310A3
Authority
WO
WIPO (PCT)
Prior art keywords
present
protein
gene
provides
treatment
Prior art date
Application number
PCT/US2003/038915
Other languages
French (fr)
Other versions
WO2004056310A2 (en
Inventor
Jeffrey A Whitsett
Stephan W Glasser
Original Assignee
Childrens Hosp Medical Center
Jeffrey A Whitsett
Stephan W Glasser
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hosp Medical Center, Jeffrey A Whitsett, Stephan W Glasser filed Critical Childrens Hosp Medical Center
Priority to AU2003302740A priority Critical patent/AU2003302740A1/en
Priority to JP2004562253A priority patent/JP2006519588A/en
Priority to EP03811670A priority patent/EP1589980A4/en
Priority to BR0317132-9A priority patent/BR0317132A/en
Priority to CA002507613A priority patent/CA2507613A1/en
Publication of WO2004056310A2 publication Critical patent/WO2004056310A2/en
Publication of WO2004056310A3 publication Critical patent/WO2004056310A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention provides for a method of treating pulmonary disease in a subject comprising the administration to a subject in need of such treatment a therapeutically effective amount of a formulation comprising a SP-C therapeutic. Preferably, the SP-C therapeutic is an agent selected from the group consisting of an isolated SP-C protein, an isolated nucleic acid molecule encoding a SP-C protein, a SP-C receptor-specific antibody that stimulates the activity of the receptor, or pharmaceutically acceptable composition thereof. The present invention also provides methods of producing a mouse with a targeted disruption in a surfactant protein C (SP-C) gene. The present invention also provides for a transgenic mouse produced by a targeted disruption in a surfactant protein C (SP-C) gene. The present invention further provides for a cell or cell line from a transgenic mouse produced by a targeted disruption in a surfactant protein C (SP-C) gene.
PCT/US2003/038915 2002-12-09 2003-12-09 Methods of diagnosis and treatment of interstitial lung disease WO2004056310A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2003302740A AU2003302740A1 (en) 2002-12-09 2003-12-09 Methods of diagnosis and treatment of interstitial lung disease
JP2004562253A JP2006519588A (en) 2002-12-09 2003-12-09 Diagnosis and treatment method for interstitial lung disease
EP03811670A EP1589980A4 (en) 2002-12-09 2003-12-09 Methods of diagnosis and treatment of interstitial lung disease
BR0317132-9A BR0317132A (en) 2002-12-09 2003-12-09 Methods of diagnosis and treatment of interstitial lung disease
CA002507613A CA2507613A1 (en) 2002-12-09 2003-12-09 Methods of diagnosis and treatment of interstitial lung disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43194902P 2002-12-09 2002-12-09
US60/431,949 2002-12-09

Publications (2)

Publication Number Publication Date
WO2004056310A2 WO2004056310A2 (en) 2004-07-08
WO2004056310A3 true WO2004056310A3 (en) 2005-09-01

Family

ID=32681947

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/038915 WO2004056310A2 (en) 2002-12-09 2003-12-09 Methods of diagnosis and treatment of interstitial lung disease

Country Status (7)

Country Link
EP (1) EP1589980A4 (en)
JP (1) JP2006519588A (en)
CN (1) CN100401896C (en)
AU (1) AU2003302740A1 (en)
BR (1) BR0317132A (en)
CA (1) CA2507613A1 (en)
WO (1) WO2004056310A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009183176A (en) * 2008-02-05 2009-08-20 Univ Of Tokyo Il-1 type ii receptor gene deletion mutant mouse
WO2010087771A1 (en) 2009-01-30 2010-08-05 Alphabeta Ab Compound and method for treatment of alzheimer's disease
WO2011162655A1 (en) 2010-06-24 2011-12-29 Alphabeta Ab Compound and method for treatment of alzheimer's disease and familial dementia
US9522170B2 (en) 2011-04-05 2016-12-20 Alphabeta Ab Methods of screening compounds for the fibril formation of Aβ peptides based on a decreased trimer/monomer ratio of a chaperone protein
CN107075470A (en) * 2014-09-18 2017-08-18 北卡罗来纳大学 Mammal lung spheroid and lung sphere cells and its application
CN111972354B (en) * 2019-05-24 2021-11-30 凯斯艾生物科技（苏州）有限公司 Method for constructing interstitial pneumonia model with autoimmune characteristics
CN111296364B (en) * 2019-10-27 2022-06-24 上海莱士血液制品股份有限公司 Gene modification method for mouse animal model and application thereof
US11895994B2 (en) 2019-10-27 2024-02-13 Shanghai Raas Blood Products Co., Ltd. Humanized knock-in mouse expressing human Protein C
CN115772539A (en) * 2022-11-17 2023-03-10 南京医科大学 Bilateral lung deficiency mouse model with I-type tracheodysplasia phenotype and construction method thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994015963A1 (en) * 1993-01-13 1994-07-21 Ajinomoto Co., Inc. Novel cell cortex protein
US6020307A (en) * 1997-04-25 2000-02-01 Ony, Inc. Compositions and methods for isolating lung surfactant hydrophobic proteins SP-B and SP-C
US20030221199A1 (en) * 1998-10-20 2003-11-27 Whitsett Jeffrey A. Surfactant protein D for the prevention and diagnosis of pulmonary emphysema
US6838428B2 (en) * 1998-10-20 2005-01-04 Children's Hospital Medical Center Surfactant protein D for the prevention and diagnosis of pulmonary emphysema
IT1308180B1 (en) * 1999-02-12 2001-12-07 Chiesi Farma Spa SYNTHETIC PEPTIDES HAVING THE ABILITY TO DECREASE SURFACE TENSION AND THEIR USE IN THE PREPARATION OF A SURFACTANT
CA2372558A1 (en) * 1999-06-11 2000-12-21 Byk Gulden Lomberg Chemische Fabrik Gmbh Pharmaceutical preparation containing modifications of surfactant protein b (sp-b) and surfactant protein c (sp-c)

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BRIDGES J.P. ET AL: "Expression of a human surfactant protein c mutation associated with interstitial lung disease disrups lung development in transgenic mice", JBC, vol. 278, no. 52, December 2003 (2003-12-01), pages 52739 - 52746, XP002988949 *
GLASSER S.W. ET AL: "The murine SP-C promoter directs type II cell-specific expression in transgenic mice", AMER J PHYSIOL LUNG CELL MOL PHYSIOL, vol. 288, 3 December 2004 (2004-12-03), pages L625 - L632, XP008049848 *
SCHWEIZER A. ET AL: "Neonatal lethality in mice deficient in XCE, a novel member of the endothelin-converting enzyme and neutral endopeptidase family", JBC, vol. 274, no. 29, 16 July 1999 (1999-07-16), pages 20450 - 20456, XP002988950 *
See also references of EP1589980A4 *

Also Published As

Publication number Publication date
CA2507613A1 (en) 2004-07-08
AU2003302740A1 (en) 2004-07-14
CN1731932A (en) 2006-02-08
JP2006519588A (en) 2006-08-31
BR0317132A (en) 2005-10-25
EP1589980A2 (en) 2005-11-02
EP1589980A4 (en) 2007-04-04
WO2004056310A2 (en) 2004-07-08
CN100401896C (en) 2008-07-16

Similar Documents

Publication Publication Date Title
JP6599394B2 (en) Scaffold compositions, methods and uses based on fibronectin type 3 domains
EA019476B1 (en) ANTI-IL-23p19 ANTIBODIES AND USE THEREOF
EA015262B1 (en) Isolated anti-il-6 antibodies and use thereof
KR20060054174A (en) Anti-amyloid antibodies, compositions, methods and uses
TW201827079A (en) Methods of treating inflammatory conditions
EA011583B1 (en) Human glp-1 mimetibodies, compositions, methods and uses
CN109432402B (en) Methods for preventing or treating certain disorders by inhibiting IL-4 and/or IL-13 binding to their respective receptors
EA016022B1 (en) Isolated mammalian anti-il-12 antibody and method for altering the activity thereof
JP2018516566A (en) Compositions for treating pathological calcification conditions and methods of using the same
JP2003527311A5 (en)
EP2330111A3 (en) Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseases
KR20080074136A (en) Use of b cell expansion agents in generating antibodies
DE60223508D1 (en) NICOTIN RECEPTOR AGONISTS FOR THE TREATMENT OF INFLAMMATORY LUNG DISEASES
WO2004056310A3 (en) Methods of diagnosis and treatment of interstitial lung disease
CN107106650A (en) For preventing or treating the disease for being characterized as abnormal fibroblast proliferation and extrtacellular matrix deposition, situation or the composition and method of process
EP1644028B1 (en) Biologically active substance of a vasoactive intestinal peptide for treating interstitial lung infections
JP3316535B2 (en) Modified mite allergen and method for producing the same
WO2002081507A3 (en) Interferon gamma polypeptide variants
CN1349403A (en) Method for treating COPD
WO2004043373A3 (en) Precursor n-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme
AT503297B1 (en) Use of antibody or its derivative for preparation of medicament for passive immunization of individual for preventing and/or treating allergic reactions in individual caused by exposure to birch pollen allergen
EP3533451A1 (en) Application of paeoniflorin-6'-o-benzene sulfonate in medicine for treating sjögren's syndrome
CN1237982A (en) Soluble polypeptides
US11472840B2 (en) Acetylcholine receptor-binding peptide
JP2002512029A5 (en)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003302740

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2507613

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003811670

Country of ref document: EP

Ref document number: 2004562253

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 20038A79839

Country of ref document: CN

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: PI0317132

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 2003811670

Country of ref document: EP